dromlakhani Head/Neck PGL Intervention Indication Assessment
STEP 1 — Gather Information
Collect clinical history (hearing loss, pulsatile tinnitus, cranial nerve deficits, neurological symptoms), physical exam, biochemical testing (plasma-free fractionated metanephrines, normetanephrines, 3-MT), imaging (contrast-enhanced MRI of head and neck, skull base CT, whole-body MRI with PET/CT if indicated), serial imaging for growth rate, and genetic testing for SDHD/SDHB if familial or multifocal; compile findings to determine presence of high-risk features.
STEP 2 — Rule In / Rule Out
If any high-risk feature is present — tympanic PGL with hearing loss, jugular bulb PGL with pulsatile tinnitus, significant skull base compression, catecholamine production, documented rapid growth on serial imaging, or metastasis — rule in for intervention; otherwise rule out for surveillance. Proceed to classification if ruled in; otherwise recommend surveillance and routine follow‑up imaging.
STEP 3 — Classify or Stratify
Sub‑classify by tumor location (tympanic, jugular bulb, carotid body, vagus nerve) and functionality (catecholamine‑producing vs non‑producing), and assess degree of skull base compression or growth rate; determine whether surgery, radiation, or a multidisciplinary approach is indicated based on the dominant risk factor.
STEP 4 — Decide
For tympanic PGL with hearing loss or jugular bulb PGL with pulsatile tinnitus, recommend surgical resection; for significant skull base compression or catecholamine production, consider surgery or primary radiation therapy; for rapid growth or metastasis, advise a multidisciplinary plan including surgery, stereotactic radiotherapy, radionuclide therapy (131I‑MIBG or 177Lu‑DOTATATE), or chemotherapy as appropriate; document decision and obtain informed consent.
Clinical Guardrails / Mimics / Pitfalls
Avoid fine‑needle cytology due to risk of hypertensive crisis and diagnostic inaccuracy; do not intervene in asymptomatic, non‑growing tumors <1 cm without high‑risk features; ensure preoperative α‑blockade if catecholamine excess is confirmed; monitor postoperative cranial nerve function; radiation may cause xerostomia, necrosis, or secondary malignancy; genetic testing results should guide surveillance intensity but are not an immediate indication for intervention.
Concrete Clinical Example
A 50‑year‑old presents with progressive unilateral hearing loss; MRI shows a 1.2 cm tympanic PGL eroding the bony septum with interval growth over 8 months; audiometry confirms conductive hearing loss; biochemical testing is normal. Decision: surgical resection recommended.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165